BOW015

1 stories · following the connections

Business

EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)

By Nasdaq OMXFeb 9, 2016, 12:00 PM UTC